Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays

Summary

About one-third of patients with non-severe haemophilia A (HA) show a discrepancy of factor (F)VIII activity (FVIII:C) measured by one-stage (FVIII:C_1st), two-stage assays or the chromogenic method (FVIII:C_chr). The aim of the study was to characterise the mutation profile in patients with FVIII:C assay discrepancies. FVIII:C discrepancy was considered significant if the calculated ratio between FVIII:C_1st and FVIII:C_chr was ≤ 0.6. In 16 patients FVIII:C_1st was higher than FVIII:C_chr. The reverse phenomenon was observed in 83 patients. Genetic analysis revealed 23 different missense mutations of which 17 were novel. Most mutations, exhibiting a higher FVIII:C_1st were localised in the A1-A2-A3 interface. The majority of mutations associated with FVIII:C_chr>FVIII:C_1st discrepancy were located close to or within the thrombin cleavage sites, FIX or vWF binding sites. Our data show a correlation between FVIII:C and thrombin generation testing with a clear differentiation between patients with haemophilia and normal controls. However, in the subgroup of FVIII:C_1st>FVIII:C_chr discrepancy, the endogenous thrombin potential and peak thrombin parameters were similar to non-discrepant haemophilia patients, while in the inverse discrepancy FVIII:C_chr>FVIII:C_1st, these variables showed values close to that of the normal control group. Certain hereditary F8 mis-sense mutations cause discrepancy in FVIII:C as measured with different assays. This can lead to failure in diagnosing HA or incorrectly classifying the severity of the disease. Therefore, we recommend that initial diagnosis of non-severe HA phenotypes should be based on results of both FVIII:C_1st and FVIII:C_chr assays.

Keywords

Haemophilia A - discrepant assay - missense mutations

• References

• 1 Langdell RD, Wagner RH, Brinkhous KM. Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assay procedure. J Lab Clin Med 1953; 41: 637-647.
• 2 Biggs R, Eveling J, Richards G. The assay of antihaemophilic-globulin activity. Br J Haematol 1955; 01: 20-34.
• 3 Seghatchian MJ, Miller-Andersson M. A colorimetric evaluation on factor VIII:C potency. Med Lab Sci 1978; 35: 347-354.
• 4 Hathaway WE, Christian MJ, Jacobsen LJ. Variant mild hemophilia Discrepancy in one stage and two stage factor VIII assays. Thromb Haemost. 1983 50. Abstract 357.
• 5 Parquet-Gernez A, Mazurier C, Goudemand M. Functional and immunological assays of FVIII in 133 haemophiliacs - characterization of a subgroup of patients with mild haemophilia A and discrepancy in 1- and 2-stage assays. Thromb Haemost 1988; 59: 202-206.
• 6 Duncan EM, Duncan BM, Tunbridge LJ. et al. Familial discrepancy between the one-stage and two-stage factor VIII methods in a subgroup of patients with haemophilia A. Br J Haematol 1994; 87: 846-848.
• 7 Rudzki Z, Duncan EM, Casey GJ. et al. Mutations in a subgroup of patients with mild haemophilia A and a familial discrepancy between the one-stage and two-stage factor VIII:C methods. Br J Haematol 1996; 94: 400-406.
• 8 Keeling DM, Sukhu K, Kemball-Cook G. et al. Diagnostic importance of the two stage factor VIII:C assay demonstrated by a case of mild haemophilia associated with His1954 Leu in theFactor VIIIA3domain. Br J Haematol 1999; 105: 1123-1126.
• 9 Schwaab R, Oldenburg J, Kemball-Cook G. et al. Assay discrepancy in mild haemophilia A due to a factor VIII missense mutation (Asn694Ile) in a large Danish family. Br J Haematol 2000; 109: 523-528.
• 10 Nesbitt IM, Hinks JL, Sampson B. et al. Discrepant one two stage FVIIIassays are very common in mild haemophilia A: correlation with FVIIIgene mutations. Thromb Haemost. 2001 Suppl: Abstract OC195.
• 11 Mumford AD, Laffan M, O_Donnell J. et al. A Tyr346 fi Cys substitution in the interdomain acidic region a1 of factor VIII in an individual with factor VIII:C assay discrepancy. Br J Haematol 2002; 118: 589-594.
• 12 Goodeve A, Hinks J, Nesbitt I. et al. Unusual discrepant factor VIII:C assays in haemophilia A patients with Tyr346Cys and Glu321Lys FVIII gene mutations. Thromb Haemost. 2001 Suppl: Abstract P1370.
• 13 Roelse J, Mertens K, van Mourik J. et al. Altered sensitivity towards factor IXa explains assays discrepancy in plasma of haemophilia A patients with GLU720LYS substitution in factor VIII. Thromb Haemost. 1999 82. Abstract 5.
• 14 Gilmore R, Harmon S, Gannon C. et al. Thrombin generation in haemophilia A patients with mutations causing factor VIII assay discrepancy. Haemophilia 2010; 16: 671-674.
• 15 Dargaud Y, Beguin S, Lienhart A, Al Dieri R, Trzeciak C, Bordet JC. et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005; 93: 475-480.
• 16 Trossaërt M, Boisseau P, Quemener A. et al. Prevalence, biological phenotype and genotype in moderate/mild hemophilia A with discrepancy between one-stage and chromogenic factor VIII activity. J Thromb Haemost 2011; 09: 524-530.
• 17 Bowyer AE, van Veen JJ, Goodeve A. et al. Specific and global coagulation assays in the diagnosis of discrepant mild hemophilia A. Haematologica. 2013 Epub ahead of print.
• 18 Schwaab R, Oldenburg J, Lalloz MR. et al. Factor VIII gene mutations found by a comparative study of SSCP, DGGE and CMC and their analysis on a molecular model of factor VIII protein. Hum Genet 1997; 101: 323-332.
• 19 White II GC, Rosendaal F, Aledort LM. et al. Definitions in hemophilia: recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.
• 20 Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
• 21 Pavlova A, Brondke H, Müsebeck J. et al. Molecular mechanisms underlying hemophilia A phenotype in seven females. J Thromb Haemost 2009; 07: 976-982.
• 22 Ngo JC, Huang M, Roth DA. et al. Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex. Structure 2008; 16: 597-606.
• 23 Hemker HC, Giesen P, Al Dieri R. et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
• 24 Goodeve AC, Peake IR. The molecular basic of hemophilia A: genotype-pheno-type relationships and inhibitor development. Semin Thromb Haemost 2003; 29: 23-30. [pic]
• 25 Poulsen AL, Pedersen LH, Hvas AM. et al. Assay discrepancy in mild aemophi-lia A: entire population study in a National Haemophilia Centre. Haemophilia 2009; 15: 285-289.
• 26 Pipe SW, Eickhorst AN, McKinley SH. et al. Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation: evidence for non-proteolytic inactivation of factor VIIIa in vivo. Blood 1999; 93: 176-183.
• 27 Pipe SW, Saenko EL, Eickhorst AN. et al. Haemophilia A mutations associated with 1-stage/ 2-stage activity discrepancy disrupt protein-protein interactions within the triplicated A domains of thrombin-activated factor VIIIa. Blood 2001; 97: 685-691.
• 28 Hakeos WH, Miao H, Sirachainan N. et al. Hemophilia A mutations within the factor VIII A2-A3 subunit destabilize factor VIIIa and cause one-stage/two-stage activity discrepancy. Thromb Haemost 2002; 88: 781-787.
• 29 Mazurier C, Gaucher C, Jorieux S. et al. Mutations in the FVIII gene in seven families with mild haemophilia. Br J Haematol 1997; 96: 426-427.
• 30 Celie PH, Van Stempvoort G, Jorieux S. et al. Substitution of Arg527 and Arg531 in factor VIII associated with mild haemophilia A: characterization in terms of subunit interaction and cofactor function. Br J Haematol 1999; 106: 792-800.
• 31 Lyall H, Hill M, Westby J. et al. Tyr346-->Cys mutation results in factor VIII:C assay discrepancy and a normal bleeding phenotype - is this mild haemophilia A?. Haemophilia 2008; 14: 78-80.
• 32 Cid AR, Calabuig M, Cortina V. et al. One-stage and chromogenic FVIII:C assay discrepancy in mild haemophilia A and the relationship with the mutation and bleeding phenotype. Haemophilia 2008; 14: 1049-1054.
• 33 Chantarangkul V, Clerici M, Bressi C. et al. Thrombin generation assessed as endogenous thrombin potential in patients with hyper- or hypo-coagulability. Haematologica 2003; 88: 547-554.
• 34 Beltran-Miranda CP, Khan A, Jaloma-Cruz AR. et al. Thrombin generation and phenotypic correlation in haemophilia A. Haemophilia 2005; 11: 326-334.
• 35 Siegemund T, Petros S, Siegemund A. et al. Thrombin generation in severe haemophilia A and B: the endogenous thrombin potential in platelet-rich plasma. Thromb Haemost 2003; 90: 781-786.
• 36 Luddington R, Baglin T. Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition. J Thromb Haemost 2004; 02: 1954-1959.
• 37 Gerotziafas GT, Depasse F, Busson J. et al. Towards a standardization of throm-bin generation assessment: the influence of tissue factor, platelets and phos-pholipids concentration on the normal values of Thrombogram-Thrombino-scope assay. Thromb J 2005; 03: 16-20.
• 38 Castroldi E, Rosing J. Thrombin generation test. Thromb Res 2011; 127 (Suppl. 03) S21-25.
• 39 Haidl H, Cimenti C, Leschnik B. et al. Age-dependency of thrombin generation measured by means of calibrated automated thrombography (CAT). Thromb Haemost 2006; 95: 772-775.
• 40 Fritsch P, Kleber M, Rosenkranz A. et al. Haemostatic alterations in overweight children: Associations between metabolic syndrome, thrombin generation, and fibrinogen levels. Atherosclerosis 2010; 212: 650-655.